Cite
HARVARD Citation
Hu, X. et al. (n.d.). Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial. Lancet oncology. 16 (4), pp. 436-446. [Online].